Related Experiment Video

Updated: May 30, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

[Testosterone substitution therapy in prostate cancer]

A Kaminsky1, H Sperling

  • 1Klinik für Urologie, Kliniken Maria Hilf GmbH, Viersener Str. 450, 41063 Mönchengladbach, Deutschland. angelika.kaminsky@mariahilf.de

Der Urologe. Ausg. A
|August 4, 2011
PubMed

Insights

Testosterone replacement therapy may be safe for men with a history of treated prostate cancer. Careful patient selection and regular monitoring are essential for managing late-onset hypogonadism (LOH) in these individuals.

Area of Science:

  • Andrology
  • Urology
  • Endocrinology

Background:

  • Testosterone levels decline with age, potentially causing late-onset hypogonadism (LOH) or partial androgen deficiency in aging males (PADAM).
  • LOH symptoms include decreased libido and erectile dysfunction, often necessitating testosterone substitution therapy (TST).

Purpose of the Study:

  • To evaluate the safety and efficacy of TST in men with a history of successfully treated prostate cancer.
  • To provide guidance on managing TST in patients with a history of localized prostate cancer.

Main Methods:

  • Review of existing data on testosterone substitution therapy in men with prior curative treatment for prostate cancer.
  • Analysis of patient outcomes regarding prostate cancer relapse and LOH symptom improvement.

Main Results:

  • Limited data suggest TST is possible without increased relapse risk in patients with previously cured prostate cancer, irrespective of treatment modality (surgery or radiation).
  • Regular surveillance and patient education are crucial for safe TST administration.

Conclusions:

  • TST can be considered for men with a history of cured prostate cancer, provided regular monitoring is in place.
  • For active or untreated prostate cancer, TST decisions require individualized risk-benefit assessment regarding disease progression.

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...